ATOR 1015
Alternative Names: ADC-1015; ATOR-1015Latest Information Update: 28 Feb 2022
At a glance
- Originator Alligator Bioscience
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Denmark (IV, Infusion)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in Sweden (IV, Infusion)
- 18 Mar 2021 ATOR 1015 is available for licensing as of 18 Mar 2021. https://alligatorbioscience.se/en/ 3569444